Novartis Investigative Site

Duarte, California 91010-3000

0 studies enrolling now · 9 studies all time

What they study most

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation, Bladder Cancer With FGFR3 Mutation or Fusion, Breast Neoplasms, Carcinoma, Renal Cell, Chronic Myelogenous Leukemia, Metastatic Renal Cell Carcinoma, Multiple Myeloma, Neoplasms, Breast, Ovarian Cancer

Studies at this site

• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer — Completed
• Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Completed
• A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies — Completed
• Study To Assess Long Term Safety Of Pazopanib — Completed
• Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma — Completed
• EXTEND (Eltrombopag Extended Dosing Study) — Completed
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed